
    
      This trial will determine the maximal dose of BusulfexÂ® that can be given in a two, three, or
      four day period with acceptable toxicity to myeloma patients, who either are > or = 65 years
      of age or have renal insufficiency, defined as creatinine > 3g/dL or creatinine clearance <
      30 ml/min.
    
  